Sign in

    Alex Lim

    Managing Director in Healthcare Investment Banking at Mizuho Securities USA LLC

    Alex Lim is a Managing Director in Healthcare Investment Banking at Mizuho Securities USA LLC, specializing in equity origination, M&A, and strategic capital raising for West Coast healthcare sector companies. He covers clients in biotech, medtech, diagnostics, and life science tools, notably having engaged with firms such as Boundless Bio, and is recognized for leading healthcare coverage efforts in San Francisco. Alex began his analyst career at Lazard before moving to Oppenheimer & Co., where he built expertise with a variety of healthcare clients, and joined Mizuho in 2017 to strengthen their North American investment banking platform. He brings a robust background in healthcare investment banking and has demonstrated leadership and deal execution skills within these sectors.

    Alex Lim's questions to Boundless Bio (BOLD) leadership

    Alex Lim's questions to Boundless Bio (BOLD) leadership • Q1 2019

    Question

    Alex Lim from Mizuho inquired about the differentiation of an AAV approach versus a lentiviral approach for Pompe disease and asked if other vectorized exon skipping therapies are in development.

    Answer

    Matt Patterson, Chairman and CEO, differentiated the approaches by describing Audentes' AAV therapy as a single IV infusion for direct tissue transduction, whereas a lentiviral approach is a more complex ex vivo cell extraction, modification, and re-implantation process. He stated the company believes the in vivo AAV approach is superior for Pompe. Regarding other vectorized exon skipping therapies, he was not aware of any specifically but noted other vectorized antisense approaches exist for diseases like Huntington's, which have some scientific similarities.

    Ask Fintool Equity Research AI